Where does Medeon Biodesign, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Medeon Biodesign, Inc. ranks #24,780 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Medeon Biodesign, Inc. hold?

Medeon Biodesign, Inc. holds 11 US utility patents granted between 2016 and 2024, spanning 4 technology areas.

What is Medeon Biodesign, Inc.'s Innovation Score?

Medeon Biodesign, Inc. has an Innovation Score of 29.7 out of 100 (32nd percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Medeon Biodesign, Inc. focus on?

Medeon Biodesign, Inc.'s top technology area is A61B (DIAGNOSIS; SURGERY; Identification) with 11 patents, ranking #1,592 of 7,127 assignees active in that subclass. Grants appear in 4 CPC subclasses total.

Is Medeon Biodesign, Inc.'s patent grant rate increasing or decreasing?

Medeon Biodesign, Inc.'s recent grant velocity is -43% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Medeon Biodesign, Inc.'s patents?

Medeon Biodesign, Inc.'s patents average 16.7 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Medeon Biodesign, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Medeon Biodesign, Inc.

USPTO PatentsView assignee record - 11 granted patents across 4 technology areas, recorded in grant years 2016–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61B (DIAGNOSIS; SURGERY; Identification).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Medeon ranks #24,780 of 49,997 tracked US assignees by granted-patent volume, with 11 patents across 4 technology areas.

#24,780
of 49,997 US assignees by volume: 32nd percentile
by Innovation Score (29.7/100): 16.7
avg claims per patent: -43%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R24780 · Foreign Corporation #24,780 · 11 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 11 grants
MID-PACK #24,780/49,997
PHOTO-FINISH Mbrico
CPC-NARROW A61B · 4 areas
INNOV-THIN 29.7/100
CLAIMS-RICH 16.7 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DROP -43% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Mbrico, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Medeon’s 29.7 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 8.6 pts (29%) Velocity 4.0 pts (13%) Breadth 7.1 pts (24%) Claim depth 10.0 pts (34%)

Qualcomm Incorporated · highest

85
Medeon Biodesign · this assignee

30
3D Lighting… · lowest

7

What this shows Medeon's Innovation Score is 29.7/100 (32nd percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Medeon?

Each dot is one of Medeon’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Medeon’s own 16.7 claims/patent is ABOVE the 15.3 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Medeon vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Medeon's grants concentrate

Medeon Biodesign, Inc. is a focused PatentsView assignee: 4 CPC subclasses with 100% of grants classified under A61B (DIAGNOSIS; SURGERY; Identification). Peak complete grant year is 2019 (4 grants) versus a trough of 1 in 2017. By volume, Medeon sits between Mbrico, LLC and Melitta Europa GMBH & Co. KG.

Medeon's three-year grant acceleration

Medeon Biodesign, Inc. shows 3 grants in 2022–2024 against only 5 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Mbrico

11
Mcci

11
MCE 5 Development

11
Mckeon Rolling St…

11
Medicomp Systems

11
Medimpact Healthc…

11
Meggitt Aerospace

11
Melitta Europa &…

11
Medeon Biodesign ◀

11

What this shows Medeon holds 11 patents at rank #24,741, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Medeon

By rank, the assignees closest to #24,741 in granted patent volume.

Leaders in A61B (Diagnosis)

Other assignees with the most granted patents in Medeon's primary technology class.

Medeon's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

30 32nd percentile higher than 32% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

Medeon Biodesign, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	2	18.2%
2017	1	9.1%
2019	4	36.4%
2021	1	9.1%
2023	1	9.1%
2024	2	18.2%

Which technologies does Medeon Biodesign, Inc. patent most?

A61B - DIAGNOSIS; SURGERY; Identification 11

G02B - Optical Elements, Systems OR Apparatus 3

A61F - Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs 1

A61L - Methods OR Apparatus FOR Sterilising Materials OR Objects IN GENERAL; Disinfection, Sterilisation OR Deodorisation OF AIR; Chemical Aspects OF Bandages, Dressings, Absorbent Pads OR Surgical ARTICLES; Materials FOR Bandages, Dressings, Absorbent Pads OR Surgical Articles 1

Top 4 of 4 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Medeon Biodesign, Inc.'s patent record in context - here's where to go next.

Medeon Biodesign, Inc.'s lead technology class is A61B (DIAGNOSIS; SURGERY; Identification), 100% of its portfolio - see every assignee active in that class. Explore A61B
Ranked #24,780 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Medeon Biodesign, Inc. against Mbrico, LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 29.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.